Last reviewed · How we verify
Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex
Approved treatments
- Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex patent landscape — cliff calendar, originator estates, attackable patents
- Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex treatment landscape brief
- Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex treatment updates RSS
Frequently asked questions about Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex
What drugs treat Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex?
Tracked treatments include Arikayce Kit.
What is the treatment for Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex?
Standard treatment for Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex includes Arikayce Kit. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex patent cliff · Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex CI report
- Treatment: Arikayce Kit · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing